Blog

AHFS Patient Medication Information Update – November 2016

The November update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs

  • Abacavir, Lamivudine, and Zidovudine (Trizivir®)
    • The combination of abacavir, lamivudine and zidovudine is used alone or along with other medications to treat human immunodeficiency virus (HIV) infection.
  • Efavirenz, Emtricitabine, and Tenofovir (Atripla®)
    • The combination of efavirenz, emtricitabine, and tenofovir is used is used alone or along with other medications to treat HIV infection in adults and children 12 years of age or older.
  • Cidofovir Injection (Vistide®; also available generically)
    • Cidofovir injection is used along with another medication (probenecid) to treat cytomegaloviral retinitis (CMV retinitis) in people with acquired immunodeficiency syndrome (AIDS).
  • Phenylephrine Nasal Spray (Little Noses®, Neosynephrine®; also available generically)
    • Phenylephrine nasal spray is used to relieve nasal discomfort caused by colds, allergies, and hay fever. It is also used to relieve sinus congestion and pressure.

FDA MedWatch Alert Revisions

FDA approved class-wide labeling changes for all prescription testosterone products, adding a new Warning and updating the Abuse and Dependence section to include new safety information from published literature and case reports regarding the risks associated with abuse and dependence of testosterone and other anabolic steroids.

  • Affected PMI monographs:
    • Testosterone Transdermal Patch
    • Testosterone Buccal
    • Oxandrolone
    • Testosterone Topical
    • Testosterone Injection
    • Testosterone Nasal Gel
    • Danazol
    • Fluoxymesterone